Transcript: NovoCure Q2 2026 Earnings Conference Call

NovoCure (NASDAQ: NVCR ) released second-quarter financial results and hosted an earnings call on Thursday.

Read the complete transcript below.

This transcript is brought to you APIs.

For real-time access to our entire catalog, please visit for a consultation.

The full earnings call is available at Summary NovoCure reported a strong second quarter 2026, with record net revenues of $184 million, marking a 16% year-over-year increase, driven by growth in Optune Gio, Lua, and Pax.

The company observed significant growth in active patients, with an 11% increase in Optune Gio and successful launches of Optune Lua in Japan and Optune Pax in the U.S. and Germany.

NovoCure updated its full-year revenue guidance to $710-$725 million and aims to achieve profitability by focusing on revenue growth and cost management, including a redesigned LUNAR-2 trial to save $90 million.

Strategic focus is on expanding the use of Tumor Treating Fields (TTFields) in new cancer indications, particularly pancreatic cancer, with plans for additional trials and IDE studies for combining TTFields with RAS inhibitors.

Management expressed confidence in continued growth and profitability, highlighting the positive reception of Optune Pax and Lua, and maintaining an enterprise-wide focus on achieving break-even adjusted EBITDA by year-end 2026.

Full Transcript OPERATOR Good day and welcome to NovoCure's second quarter 2026 earnings call.

At this time all participants are in listen-only mode.

After the speaker's presentation there will be a question-and-answer session.

To ask a question you will need to press star 11 on your touchtone telephone.

Please note this call is being recorded.

I would like to turn the call over to Adam Daney, Head of Investor Relations.

Please go ahead.

Adam Daney, Head of Investor Relations Good morning, and thank you for joining us to review NovoCure's second quarter 2026 performance.

I'm joined on the phone today by our Executive Chairman Bill Doyle, CEO Frank Leonard, Chief Innovation and Medical Officer Uri Weinberg, and CFO Christoph Brackmann.

For your reference, slides accompanying this earnings release can be found on our website, on the Investor Relations page under Quarterly Results.

Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements.

These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings.

We do not intend to update publicly any forward-looking statements except as required by law.

Where appropriate, we will refer to non-GAAP financial measures to evaluate our business, specifically Adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization and share-based compensation.

We believe Adjusted EBITDA is an important metric as it removes the impact of earnings attributable to our capital structure, tax rate and material non-cash items, and best reflects the financial value generated by our business.

We do not provide forward-looking guidance for Adjusted EBITDA on a GAAP basis due to the inability to predict share-based compensation expenses contained in the reconciled GAAP measure, net income, without reasonable efforts.

Reconciliations of non-GAAP to GAAP financial measures are included in our press release, earnings slides and our Form 10-Q filed with the SEC today.

These materials can also be accessed from the Investor Relations page of our website.

Following our prepared remarks this morning, we will open the line for your questions.

I will now turn the call over to our Executive Chairman, Bill Doyle.

Bill Doyle, Executive Chairman Thank you, Adam.

This morning we reported our second quarter 2026 results, and I am pleased to say this was our strongest commercial quarter to date with record net revenues and active patients on therapy.

We continue to build on the momentum of the first quarter and have also made meaningful progress on our path to profitability.

I will begin this morning with a review of our commercial results.

Frank will then provide an update on our clinical strategy.

Christoph will conclude our prepared remarks with a review of our quarterly financial performance before we open the line for questions.

All three of our approved products contributed to our commercial performance this quarter.